Cytarabine
Chemical Structure
Overview
Cytarabine, is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin’s lymphoma.It is given by injection into a vein, under the skin, or into the cerebrospinal fluid.There is a liposomal formulation for which there is tentative evidence of better outcomes in lymphoma involving the meninges.
Key Features
- Molecular Formula C9H13N3O5
- Therapeutic Category Nucleoside Metabolic Inhibitor
- API Technology High Potent
- Dose Form Injectables
Use In
-
Acute Myeloid Leukemia (AML)
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
-
Acute Lymphocytic Leukemia (ALL)
Cytarabine is used to prevent and treat leukemia that has spread to the meninges (the three membranes that cover the brain and spinal cord). It is also use with other drugs to treat acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia.
| Open Part | Close Part | IP | BP | USP | EP |
|---|---|---|---|---|---|
| Under preparation | Under preparation |  |
|
|
|